Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for JAML drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | JAML ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View JAML Products |
| Gene Delivery | JAML Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View JAML Products |
| Benchmark Ab | Anti-JAML Recombinant Antibody Recombinant positive control for assay validation. |
View JAML Products |
| Validator | JAML siRNA Set For knockdown verification in functional assays. |
View JAML Products |
| Related Target A | CXADR Primary physiological ligand of JAML; essential for ligand-binding blockade assays. |
View CXADR Products |
| Related Target B | F11R Homologous junctional adhesion molecule (JAM-A) used for specificity counter-screening. |
View F11R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity |
| Subfamily counter screening | Homolog panel proteins (JAM-A/B/C) strictly verified by mass spectrometry |
| Lack of Controls | Recombinant benchmark antibodies included for assay standardization |
| False Positives | Sequence-verified siRNA included for target knockdown specificity checks |
Live JAML R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for JAML (Junctional Adhesion Molecule-Like, also known as AMICA1) therapeutics is intensifying, with major players shifting focus from traditional systemic anti-inflammatory agents to targeted monoclonal antibodies (mAbs) and antagonist fusion proteins. As first-generation therapies targeting leukocyte transmigration reach the clinic, the next wave of R&D is targeting JAML’s role as an immune checkpoint in the tumor microenvironment and a key driver of chronic barrier tissue inflammation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic & Biopharma Consortia | Psoriasis, Rheumatoid Arthritis | Blockade Assay (Need high-purity JAML ECD-Fc and CXADR) |
| Soluble Decoy Receptor | Biotech Startups | Acute Kidney Injury, Wound Healing | Affinity & Kinetics Validation (Need HEK293-expressed JAML) |
| Immune Checkpoint Inhibitor | Oncology-focused Biopharma | Solid Tumors (T-cell modulation) | Functional Cell-based Assays (Need JAML Lentivirus for stable cell lines) |